AngioDynamics, Inc. (NASDAQ:ANGO) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGOFree Report) by 3.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,292 shares of the medical instruments supplier’s stock after buying an additional 4,765 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.34% of AngioDynamics worth $996,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ANGO. Algert Global LLC raised its position in AngioDynamics by 126.9% during the third quarter. Algert Global LLC now owns 118,340 shares of the medical instruments supplier’s stock worth $865,000 after acquiring an additional 66,180 shares during the period. Dark Forest Capital Management LP acquired a new position in shares of AngioDynamics during the 3rd quarter worth about $85,000. Acadian Asset Management LLC purchased a new position in AngioDynamics in the 3rd quarter valued at about $2,630,000. Hsbc Holdings PLC boosted its holdings in AngioDynamics by 61.2% in the 3rd quarter. Hsbc Holdings PLC now owns 39,370 shares of the medical instruments supplier’s stock worth $287,000 after buying an additional 14,946 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in AngioDynamics by 7.3% during the 3rd quarter. Envestnet Asset Management Inc. now owns 125,317 shares of the medical instruments supplier’s stock worth $916,000 after buying an additional 8,565 shares in the last quarter. Hedge funds and other institutional investors own 90.52% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ANGO. Raymond James decreased their target price on AngioDynamics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 9th. HC Wainwright lowered their target price on shares of AngioDynamics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, January 8th.

View Our Latest Analysis on ANGO

AngioDynamics Price Performance

ANGO stock opened at $5.50 on Friday. AngioDynamics, Inc. has a 1 year low of $5.26 and a 1 year high of $12.70. The firm has a market capitalization of $219.18 million, a PE ratio of -15.71 and a beta of 0.66. The business has a 50 day simple moving average of $6.34 and a 200-day simple moving average of $6.88.

AngioDynamics (NASDAQ:ANGOGet Free Report) last issued its earnings results on Friday, January 5th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. AngioDynamics had a negative return on equity of 1.78% and a negative net margin of 4.28%. The company had revenue of $79.07 million during the quarter, compared to analysts’ expectations of $81.65 million. On average, equities research analysts expect that AngioDynamics, Inc. will post -0.43 EPS for the current year.

About AngioDynamics

(Free Report)

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.

Further Reading

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.